Drug Type Synthetic peptide |
Synonyms Hepalatide, N-TIDE, L47 |
Target |
Mechanism NTCP binders(Sodium/bile acid cotransporter binders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis D, Chronic | Phase 2 | CN | 07 Oct 2023 | |
Hepatitis D, Chronic | Phase 2 | MN | 07 Oct 2023 | |
Hepatitis B, Chronic | Phase 2 | CN | 24 May 2021 | |
Diabetes Mellitus | IND Application | US | 30 Jan 2022 | |
Diabetes Mellitus | IND Application | CN | 30 Jan 2022 | |
Hepatitis D | Preclinical | CN | 30 Jan 2022 |
Phase 2 | 96 | Group A (2.10 mg) | gpiaqijzyy(roasdheiiv) = the adverse events (AEs) were generally grade 1 or 2, and most were identified to be related to PegIFN, such as fever, headache, fatigue, leukocytosis, neutropenia. No treatment-related serious AEs were reported. kohyeqjiet (igknxvufbr ) | - | 21 Jun 2023 | ||
Group B (4.20 mg) |